| Drug Name |
Hydralazine |
| Drug ID |
BADD_D01081 |
| Description |
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691]
Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779] |
| Indications and Usage |
For the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
C02DB02 |
| DrugBank ID |
DB01275
|
| KEGG ID |
D08044
|
| MeSH ID |
D006830
|
| PubChem ID |
3637
|
| TTD Drug ID |
D0K1XK
|
| NDC Product Code |
Not Available |
| Synonyms |
Hydralazine | Hydrallazin | Hydrazinophthalazine | Apressin | Nepresol | Hydralazine mono-Hydrochloride | Hydralazine mono Hydrochloride | mono-Hydrochloride, Hydralazine | Apressoline | Apresoline | Hydralazine Hydrochloride | Hydrochloride, Hydralazine |
